Analysis and Identification of Putative Novel Peptides Purified from Iranian Endemic Echis Carinatus Sochureki Snake Venom by MALDI-TOF Mass Spectrometry

Analysis and Identification of Some Putative Novel Peptides Purified from Iranian Endemic Echis carinatus Sochureki Snake Venom by MALDI-TOF Mass Spectrometry. Archives

Dysregulation of hemostasis arrangement, one of the body's key organs that contributes to the balance of bleeding and coagulation, is among the most severe clinical symptoms following the envenomation of several genera from all four families, such as Colubridae, Elapidae, Viperidae, and Atractaspididae.Identification of substances from snake venom that interferes with coagulation cascade and platelet aggregation mechanisms has contributed immensely to deciphering the details of molecular reactions involved in physiological functions.Additionally, these findings have enabled us to design various novel anti-coagulant, pro-coagulant, platelet aggregation inducers, and inhibitor therapeutic factors, visualizing new perspectives in the treatment of thromboembolic, bleeding, clotting, cardiovascular, and hematological disorders (7,13,14).
Further research is needed to delineate the structurefunction relationships and to understand the exact mechanism of new anti-coagulants, pro-coagulants, platelet aggregation inducers, and platelet aggregation inhibitors agents.The majority of pro-coagulant proteins of snake venom are divided into four main classes: factor V activators, factor X activators, prothrombin activators, and thrombin-like enzymes, or fibrinogenases.Anti-coagulant molecules from snake venoms are divided into phospholipases A2 (PLA2), fibrin (ogen) olyticsnake venom metalloproteinases (SVMPs), protein C activators, Lamino acid oxidases, C-type lectin-like proteins (snaclecs or SVCLPsC-type lectin-like proteins from Snake Venom. Snake Venom C-type lectin-like proteins.C-type lectin-like proteins from Snake Venom.Snake Venom C-type lectin-like proteins), three-finger toxins, and Kunitz-type proteinase inhibitors (4,(14)(15)(16)(17).Echis carinatus (EC; Scientific name: Echis carinatus sochureki; English name: Sind saw-scaled viper; Persian name: Jafari snake) is a member of the Viperidae family.Echis carinatus is a venomous snake with a wide distribution in the deserts of Iran (18,19).The venom of EC contains a mixture of proteins and peptides that act against or in parallel with pro-coagulant, anti-coagulant, fibrinolysis activity, and platelet function (4,14,15,20,21).Achieving the pro-and anti-coagulant fractions from a natural source such as venom can be very valuable in the therapeutic field and anti-venom production technology; moreover, their potential medicine perspectives are beneficial for occlusive arterial or venous thromboembolism.Ecarin (22), Carinactivase (23), and EC-PIII (24) are examples of pro-coagulant fractions purified from E. carinatus venom.Multiactivase, a pro-coagulant agent, is purified from Echis multisquamatus venom (25).EC-PIII, a novel pro-coagulant factor, is introduced from the venom of EC.Mukherjee et al. (2017) investigated the procoagulant and anti-coagulant profiles of EC snake venom (26).Mirakabadi et al. and Vatanpour et al. have examined the anti-coagulant, pro-coagulant, and anti-platelet properties of Iranian Echis carinatus (IEC) snake venom (27)(28)(29).Moreover, Echistatin purified from the venom of the EC, is an anti-platelet agent (30).
Nevertheless, our knowledge has not shed much light on the possible roles of newly discovered agents, especially agents that affect the homeostasis system, derived from Iranian endemic snake venom at the physiological level.Considering that there are a lot of geographical distributions of the Viperidae family throughout Iran and the importance of medicinal products originating from natural sources, further research must be performed to better understand the incredible versatility of toxins causing homeostasis organization.Our study for the first time focuses on the purification, structure, and functional characterization of pro-coagulant, anti-coagulant, and anti-platelet agents isolated from Iranian endemic EC snake venom using matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF/MS).

Biological material and venom extraction
The lyophilized IEC crude venom was obtained from the Department of Venomous Animals and Antivenom Production, Razi Vaccine and Serum Research Institute, Karaj, Iran.

Protein determination
The Lowry assay was applied to determine the total protein of IEC crude venom and its fractions.It is noted that BSA was considered standard (31, 32).

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
The molecular mass of purified fractions/subfractions and crude venom was examined by 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis )SDS-PAGE( according to the method of Laemmli (32,33).

In vitro assessment 2.7.1. Human plasma
The blood samples were collected from healthy individuals (20-30 years) without a history of bleeding or thrombosis with their consent (Ethical approval number: IR.SBMU.RETECH.REC.1398.620).The whole blood was centrifuged at 2,500 rpm for 20 min at 4°C.The platelet-poor human plasma (PPP) was used for pro-coagulant experiments.

Recalcification time
The recalcification time assay was performed as described previously (35).

Prothrombin time
Crude venom samples and purified proteins (50 µl), plasma (100 µl), and PT reagent (50 µl) were preincubated for 3 min at 37°C.Afterward, crude venom/isolated proteins and PT reagent were mixed and then shaken for 30 s. Plasma clot formation time was recorded using a chronometer after adding plasma and shaking at 37°C for 5 s.

Activated partial thromboplastin time
Crude venom samples and purified proteins (50 µl), plasma (100 µl), and APTT reagent (50 µl) were preincubated for 3 min at 37°C.Subsequently, crude venom/isolated proteins, CaCl2 (50 µl), and APTT reagent were mixed.The mixture was shaken for 20 s at 37°C.Plasma clot formation was recorded by chronometer after adding plasma and shaking in the lab lamp lighting.

Thrombin clotting time and fibrinogenclotting activity
Thrombin clotting time (TCT) was determined using a commercial kit (STA®-Thrombin kit [REF 00611]) and a manual coagulation analyzer (PKL PPC 170).Thrombin clotting time was measured after incubating 100 µl plasma at 37°C for 2 min.Thrombin time was recorded by a manual coagulation analyzer after adding 100 µl of mixed thrombin reagent and the sample (crude venom samples/fractions/subfractions).Fibrinogen-clotting activity (FCA) was determined using a commercial Fibri-Prest® 2 Kit (00608,100045), in a water bath based on its instructions.Briefly, 100 µl fibrinogen reagent and 200 µl of diluted human plasma (1:10 concentration/PH=7.4)were incubated at 37°C for 2 min.Next, 200 µl plasma, 100 µl of crude venom samples/fractions/subfractions, and 100 µl fibrinogen reagent were mixed and then shaken in a water bath.The fibrinogen concentration was estimated from a fibrinogen standard DIAGNOSTICA STAGO (100045).

Platelet aggregation assay 2.7.3.1. Human plasma
Blood donors who had taken drugs to interfere with platelet reactions, such as aspirin and other nonsteroidal anti-inflammatory drugs, or thienopyridines, including ticlopidine and clopidogrel, two weeks before the experiment, were excluded from the study.Blood samples were collected from a forearm vein with a vacuum syringe equipped with 8.5-mL plastic centrifuge vacuum tubes containing 1.5 volumes of acid-citrate-dextrose anti-coagulant.The tubes were immediately placed in a water bath at 37°C for 15 min.Washed platelet preparation was carried out according to the modified Preparation of Washed Human Platelets (Platelet aggregation using washed human platelets) method (36,37).Platelet aggregation was measured in a CHRONO-LOG® Model 700 Whole Blood/Optical Lumi-Aggregometer (Pennsylvania, USA).Assays were performed in magnetic siliconized cuvettes under stirring.Aggregation was started by adding collagen or arachidonic acid agonists (Control), crude venom samples/fractions/subfractions (Sample1), and mixed collagen or arachidonic acid agonists and crude venom samples/fractions/subfractions (Sample2) to washed platelets.The amount of 100% aggregation was recorded with supra-maximal collagen or arachidonic acid agonists concentrations (36,37).2.8.In vivo assessment 2.8.1.Assessment of hemorrhagic activity 100 µl of the various doses of IEC crude venom (0.01, 0.1, and 1 mg/mL) or purified proteins were subcutaneously injected into the shaved back skin of mice to assess the IEC crude venom and its fractions hemorrhagic activity.After 24 h, the mice were suffocated due to gas inhalation in a particular container (Desiccator).The mice's hemorrhagic points generated subcutaneously were observed and determined.The control group was injected with 100 µl of normal physiological saline solution and ammonium acetate instead of the samples (crude venom/fractions/subfractions), respectively .

Defibrinogenating activity
The defibrinogenating activity of the samples (crude venom/fractions/subfractions) was determined by injecting mice at a constant volume of 200 µl (using normal saline as a diluent) intravenously into the vein of mice.The control group received a similar injection of normal saline solution.After one hour, animals were anesthetized, and blood samples were collected by cardiac puncture.The blood samples from each animal were placed in a new glass clotting tube without any additives and left at room temperature, and the presence or absence of clots was recorded by gently tilting the tube.

Purification protocol
IEC crude venom (100 mg) was fractionated using a gel chromatographic Sephadex G-50 column (150×2 cm).It was pre-equilibrated with ammonium acetate buffer (0.05 M, pH 7.4).Fractionation was carried out at a flow rate of 30 ml/min -1 under isocratic conditions with the same buffer.The effluent was monitored at 280 nm.We obtained five fractions (i.e., EC1, EC2, EC3, EC4, and EC5).Each fraction was collected to measure the anti-coagulant and pro-coagulant capacities.A dose (10 mL of EC1 fraction with 933 µg/ml), after concentrated by ultrafiltration, was dissolved in 10 ml of 20 mM Tris-base buffer (pH 8.2) and was passed continuously into the ionexchange column (20×1.6 cm) at a flow rate of 30 ml/h -1 .The effluent was monitored at 280 nm by a spectrophotometer (UV752S, Lengguang Co., China).The DEAE-Sepharose column was equilibrated with Tris-base buffer (20 mM, pH 8.2).Then, 0-1.0 M NaCl solution was passed through the chromatography column with a linear gradient.Each fraction was collected to be examined by coagulant tests.The fraction (namely EC1.5) with the highest pro-coagulant property was selected for the following purification.The EC1.5 and EC4 were further purified by reversed-phase (RP)-HPLC.These samples were injected into an HPLC system (600, Waters, USA) equipped with a C4 and C18 column (5 μm, 9.4×250 mm, Agilent Inc., USA) for EC1.5 and EC4, respectively.The elution was carried out with a linear gradient of ACN containing 0.1% (v/v) TFA at a flow rate of 0.5 ml/min -1 and water containing 0.1% (v/v) TFA at a flow rate of 0.5 ml/min -1 over 60 min.
Excitation wavelengths of 215 and 280 nm were applied for monitoring the different peptide fraction peaks and then were collected manually for the procoagulant activity and hematological assays.The purification profile of EC5.1(b) subfraction had been mentioned in a previous study (32).

Mass spectrometry and database searching 2.10.1. MALDI-Mass method
The gel was fixed in a solution containing 45% deionized water, 45% methanol, and 10% acetic acid for 2 h.Coomassie blue color was applied for highlighting separated bands on gel electrophoresis overnight.After this time, single bands of EC1.5(a), E.C5.1(b), and EC4(a) were extracted and placed into Eppendorf tubes.In-gel digestion protocol using trypsin was applied to produce peptide segments that had been broken at the lysine-arginine bonds (38).Based on molecular mass data, prediction of the partial structure of E.C1.5(a), EC5.1(b), and EC4(a) was obtained using MALDI-TOF/MS analysis.The obtained m/z values of the peptide ions of the E.C1.5(a), EC5.1(b), and EC4(a) were matched to the Mascot database to identify some matched peptides.Matrixassisted laser desorption/ionization-time of flight mass spectrometry (Applied Biosystems 4800 MALDI TOF/MS, Nd: YAG 200-HZ laser) was used for MS experiments.For MS analysis, the digested sample was spotted on a MALDI plate mixed with CHCA in 50% ACN containing 0.1% TFA (with a 1:2 ratio respectively) as a matrix solution, air dried, and analyzed in reflector positive mode (the mass range was 800-4000 Da).The MALDI-TOF/MS data were interpreted and processed using the Mascot database.

Alignment
The ClustalW, BioEdit 7.2.6, and BLASTP algorithm (blast.ncbi.nlm.nih.gov/Blast.cgi)methods were used for homology search and analysis of the multiple sequence alignment.

Bioinformatics analysis
Predicted putative three-dimensional structures of the E.C1.5(a), EC5.1(b), and EC4(a) according to the data obtained from Mascot analysis were modeled by Molegro Data Modeller 3.0 software.

Statistical analysis
The general linear model procedure in SAS 9.1 software was applied to examine the significance of the difference in activated clotting time and pharmacological assays of IEC crude venom and its fractions as control.The values were reported as the mean±SD.The p-value of ≤ 0.05 was considered significant.

Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
The molecular mass profile of samples (crude venom/fractions) varied from 6.5 to 200 kDa (Fig. PCT, RT, PT, and APTT tests were applied for samples (crude venom/fractions/subfractions) that were purified from several stages of chromatography.The fractions (EC1, EC2) with the highest procoagulant capacity and the fraction (EC5) with the anti-coagulant capacity were candidates for further modified, improved, and reproducible purification.Here, EC1, EC4, and EC5 fractions are discussed.The hematological results are summarized in Table 1.The PCT assay was performed for different prepared concentrations of EC1, EC2 fractions, and subfractions of EC1: EC1.5 and EC1.6.The dose-dependent profile of PCT is shown in Fig. SD 4, SD 5, SD 6, and SD 7. In RT, PT, and APTT assays, EC1, EC1.5, and EC1.5(a) indicated a significant decrease compared to the control (P=0.0001), while EC5.1(b) showed a significant increase in comparison to the control (P=0.0001).In RT, PT, and APTT assays, no significant differences were found between samples and control in EC4 (P>0.05).

Defibrinogenating activity
The results of the defibrinogenating activity of the samples (crude venom/fractions/subfractions) are presented in Table 1.In in vivo defibrinogenating assessment, one hour after the administration of these fractions, the concentration of fibrinogen in the mice plasma decreased in a concentration's proteindependent manner (EC1-EC4, EC1.5, EC1.6, and EC1.5(a)), leading to an increase in the coagulation time of the blood taken from mice's heart.

Alignment
The highly considerable homology of the purified peptides with Viperidae venom protein families in protein databases was shown by multiple sequence alignment (Fig. SD 8,9).

Bioinformatics analysis
The nearest 3D structures of EC1.5(a), EC5.1(b), and EC4(a) resulting from bioinformatics analysis according to the data resulting from Mascot analysis are illustrated in Fig. SD8.
As reported in the study by Mukherjee in 2017, EC venom contains both pro-coagulant and anti-coagulant proteins (26).In the current study, the novel procoagulant, anti-coagulant, and anti-platelet agents were purified from the venom of Iranian endemic ECby multi-step chromatography.This procedure was performed based on a novel platform for obtaining homogeneous IEC snake-venom pro-coagulant, anti-coagulant, and anti-platelet fractions, named EC1.5(a),EC5.1(b), and EC4(a) to a high degree, which were observed as a single-band protein of 66, 7.5, and 5 kDa on the gel electrophoresis, respectively.The procoagulant potential has been reported in various snake venoms (39).According to the results of PMF analysis (Table 1 SD), the protein sequence coverage of EC1.5(a) was calculated at 100%, 100%, 98%, 63%, 53%, 47%, 38%, 35%, 34%, 10%, and 8% homologous in sequence to Zinc metalloproteinasedisintegrin-like uracoina-1 (Fragment), Disintegrin  metalloproteinase/disintegrin echistatin (Fragment), and Zinc metalloproteinase-disintegrin VMP-I, respectively.Therefore, it is expected that this is a P-ΙΙ metalloproteinase that corresponds to the venom metalloproteinase (M12B), P-IIa sub-subfamily with disintegrin domains.SVMPs, according to their sizes and domains, are classified into four groups: P-I, P-II, P-III, and P-IV classes.P-II class, the medium-size SVMPs (30-65 KDa), constitute proteinase and disintegrin domains.In this group, the Arg-Gly-Asp (RGD) sequence of the many disintegrin domains was replaced by another sequence.An example of this group is bilitoxin-1, which is a Met-Gly-Asp (MGD) sequence instead of an RGD sequence and lacks a platelet aggregation inhibitory effect (8,40,41).Former studies have shown that only two key coagulation proteins, such as factor X (FX) and prothrombin activator, could be activated by SVMPs to cause their pro-coagulant effects (12).Calcium ions are essential to activate Factor X (8,12,42).In the present study, EC1.5(a), a potent pro-coagulant agent, showed the coagulation of citrated human plasma in PCT assay without the addition of CaCl2 or any other cofactors.It is, therefore, concluded that EC1.5(a) is thought more likely to be a prothrombin activator because calcium ions are not needed for the activity of cofactor-independent coagulation proteins.In other words, the amount of calcium ions is insufficient to trigger a coagulation cascade via cofactor-dependent coagulation factors because of the calcium-chelating activity of sodium citrate.EC1.5(a) is also a platelet aggregation inducer.Snake venoms that have represented platelet aggregation effects are classified into two groups: some release reactions and induce aggregation and others inhibit platelet aggregation (12).EC1 and EC1.5(a) showed aggregation inducer activity on washed human platelets without adding any agonist.Further experiments must be performed to reveal that platelet aggregation characteristics are due to the indirect generation of thrombin from prothrombin residue or due to the direct proteolytic effect on the platelet membrane receptors.Another feature confirmed for these metalloproteinases is hemorrhagic activity.Systemic and local hemorrhage is a common pathological complication of Crotalidae and Viperidae snakebites that can be attributed to metalloproteinases (26) .EC1.5(a) elicits a hemorrhagic response, and compared to EC venom (1 mg/mL), EC1.5(a) (47.8 µg/mL) shows hemorrhagic activity with less intensity.The results of defibrinogenating activity demonstrated an increase in the coagulation time of the blood taken from the injected mice heart.This event occurs due to the employment of specific plasma proteins (e.g., coagulation cascade factors), the fall of platelet, and the activation of the fibrinolytic system by procoagulant toxins (e.g., EC1.5(a)).
One of the most important events that occur following a snakebite by EC is a considerable reduction of fibrinogen in addition to an increase in fibrinogen degradation products (26).Clinically, these events lead to declining concentrations of fibrinogen and other blood factors resulting in a potentially lethal pathological syndrome, known as Disseminated Intravascular Coagulation and Venom-Induced Consumption Coagulopathy (26).In victims of snakebites, this causes intravascular coagulation, leading to cardiovascular collapse.In human victims, the employment of the majority of available essential clotting factors to the formation of millions of microthrombies following the dilution of the venom into a much larger blood volume can be lethal.Coagulopathy also contributes to internal hemorrhages, such as cerebrovascular accidents (23, 43-47).Ecarin is the best candidate for group A prothrombin activators.This Ca 2+ -independent procoagulant protein was isolated and purified from the venom of the EC (Kenya carpet viper or saw-scaled viper) by Morita et al. (1987).It is a P-III metalloprotease with 426 amino acids and shares 64% similarity to the heavy chain of RVV-X (Russell's viper venom factor X activator) from Daboia russelli (43).
Ecarin has no inhibitory effect on platelet aggregation because of the replacement of RGD sequence with MDC domains in the disintegrin-like domain.Previous studies have also reported that Ecarin is a platelet inducer.It has even been reported to induce platelet aggregation despite the presence of disintegrin domains (48)(49)(50).A few SVMPs have been reported to induce platelet aggregation.Alborhagin and crotarhagin, which are SVMPs from Trimeresurus albolabris and Crotalus horridus horridus snake venom, respectively, induce platelet aggregation through a mechanism involving Glycoprotein VI (12,26).EoVMP3 another SVMP platelet aggregation inducer from the venom of Echis species, the first fraction being Ecarin (50).EoVMP3 is SVMP class P-III metalloendopeptidases consisting of metalloproteinase, disintegrin-like, and cysteine-rich domains (50).Ecarin does not independently induce aggregating washed platelets [32].In contrast, EoVMP3 and EC1.5(a) can aggregate platelets independently of plasma (50).EC1.5(a) has procoagulant and aggregation activities on washed human platelets, which may show the replacement of the platelet inhibitor sequence in a disintegrin-like domain similar to Ecarin.The full characterization of the mechanism of EC1.5(a) activity and its interaction with platelets requires further studies.
Halystase is a serine protease isolated from Agkistrodon halys blomhoffii snake venom.Although it has an RGD sequence, it did not inhibit the platelet aggregation induced by adenosine diphosphate (ADP) and collagen (51).Ecarin clotting time is a laboratory test used to assay anticoagulation during treatment with hirudin (22,34).Chudzinski-Tavassi et al. (2005) introduced insularinase A, which belongs to the class P-I fibrin(ogen)olytic metalloproteases and is functionally a member of group A prothrombin activators (52).Insularinase A, similar to Ecarin and in contrast to EC1.5(a), did not show hemorrhagic activity.It has a pro-coagulant effect independent of any cofactors like EC1.5(a) (Silva et al., 2003;Nishida et al., 1992) (52,53).
Another example of pro-coagulant agent is berythractivase, which was previously described as a novel prothrombin activator enzyme, was isolated from Bothrops erythromelas (jararaca-da-seca) snake venom (Chudzinski-Tavassi et al., 2003).Similar to EC1.5(a), it contains metalloproteinase, disintegrin-like, and cysteine-rich domains.In contrast to EC1.5(a), berythractivase showed no hemorrhagic activity.According to the results, although the basic structure of berythractivase is related to snake-venom hemorrhagic metalloproteinases and is functionally identical to group A prothrombin activators, it is a prothrombin activator without hemorrhagic response.
Additionally, the role of DCD in its disintegrin-like domain of berythractivase in platelet function has not yet been explored (44).
Basparin A has been noted as a pro-coagulant metalloproteinase, from the venom of the Crotaline snake (Bothrops asper), inhibiting platelet aggregation as well as inducing defibrination and thrombosis (Gutiérrez et al., 2003).Apart from its clotting activity, basparin A can obstruct collagen-dependent platelet aggregation in vitro.Basparin A is a singlechain P-III metalloproteinase structured like EC1.5(a), with the metalloproteinase, disintegrin-like, and highcysteine domains.In contrast to EC1.5(a), Basparin A lacks hemorrhagic effects; it has pro-coagulant activity, independent from additional cofactors; therefore, similar to EC1.5(a).It shows a higher clotting ability in human plasma similar to EC1.5(a) (54).
Babaie et al. in 2013 introduced one pro-coagulant fraction from Iranian saw-scaled viper (EC) with a molecular weight of about 65 kDa and potent procoagulant activity on PPP without the requirement of any cofactors similar to EC1.5(a) (29).Velmurugan reported a novel P-III class pro-coagulant SVMP from Indian EC venom named EC-PIII and displayed a procoagulant effect under in vitro conditions similar to EC1.5(a).It is devoid of hemorrhagic, unlike EC1.5(a) (24).RVV-X (Russell's viper venom factor X activator) is a pro-coagulant agent purified by Williams and Esnouf in 2003 from Daboia russelli.It consists of a metalloproteinase, a disintegrin, and a cysteine-rich domain similar to EC1.5(a).The structure of factor X activator RVV-X is very similar to that of carinactivase-1 from EC leucogaster.Unlike EC1.5(a), it requires Ca 2+ ions at millimolar concentrations for optimal activity (55).
The circulatory system is one of the vital physiological systems of the body attacked by the anti-coagulant PLA2 from snake venom (26).Crude venom mixture consists of several isoforms of PLA2, which are classified as acidic, basic, or neutral PLA2 enzymes according to their overall net charge.The mechanism of anti-coagulant action of snake venom PLA2 enzymes is to destroy or make unavailable procoagulant phospholipids that are necessary for starting the coagulation cascade.Some of the PLA2s can bind to other blood coagulation factors, such as factor Xa, factor Va, prothrombin, and thrombin, or inhibit the formation of prothrombinase complex (complex of factor Xa, factor Va, phospholipids, and Ca 2+ ) and thus can inhibit the initiation of blood clotting pathway (56).
In comparison to the anti-coagulant introduced by other researchers, we can mention Cc1-PLA2 and Cc2-PLA2, two PLA2s purified from Cerastes cerastes venom.The anti-coagulant effect is due to the interaction of them with factor FXa through a noncatalytic PL-independent mechanism leading to no released thrombin.These agents also have antiplatelet activity similar to EC5.1(b) (57).NnPLA2-I, acidic PLA2 purified from Indian cobra (Naja naja) venom, has both anti-coagulant and anti-platelet activities similar to EC5.1(b) (58).Daboxin P, a major PLA2 enzyme from the Indian Daboia russelii venom, targets both factor X and factor Xa for its anticoagulant activity (59).The results of a study by Babaie showed that F2C and F2D fractions from IEC venom could delay the prothrombin time, and thus can be considered anti-coagulant factors.They suggested that the anti-coagulant activity of these fractions could be caused by proteolytic enzymes (27).
Mirakabadi introduced EC217 as an anti-coagulant fraction from IEC venom and showed that the venom of EC contains at least one anti-coagulant factor (60). Wilkinson et al. reported that PLA2s were the most likely candidates responsible for anti-coagulant effects stimulated by Naja nigricollis venom (3).Damotharan et al. designed to purify a novel anti-clotting PLA2 component from the sea snake venom of Enhydrina schistose.They suggested that this fraction could be a candidate for the development of novel compounds for pharmacological applications in the near future (61).EC4(a) inhibits both pathways of platelet aggregation induced by collagen and arachidonic acid.The results of the PMF analysis showed that this fraction was Echistatin-like.According to the results of PMF analysis (Table 3 SD), the protein sequence coverage of EC4(a) is 67%, 38%, and 34% homologous in sequence to Disintegrin Echistatin-alpha, Disintegrin Echistatin-beta, and Disintegrin Echistatin-gamma, respectively.
Echistatin, a platelet aggregation inhibitor, was purified from the venom of the EC (saw-scaled viper).It inhibits platelet aggregation by binding to the GP IIb/IIIa receptors throughout the RGD sequence.It inhibits platelet aggregation stimulated by ADP, thrombin, epinephrine, collagen, or platelet-activating factor (30) In conclusion, EC venom contains components that exhibit both pro-and anti-coagulant properties.To the best of our knowledge, this was first study to introduce three fractions of EC and their functions on the hemostatic system by MALDITOF MS.EC1.5(a), metalloproteinase/disintegrin region with disintegrinlike domains, is platelet aggregation inducer on human washed platelets that possesses strong procoagulant effect without the addition of calcium and any other co-factors.Similar to other metalloproteinases, it displays hemorrhagic activity.This factor decreases the thrombin and fibrinogen time compared to the control.Non-hemorrhagic EC5.1(b), with structural similarity to PLA2, is a strong anti-coagulant that inhibits the aggregation of humanwashed platelets induced by collagen and arachidonic acid, and non-hemorrhagic EC4(a) is an Echistatin-like with platelet aggregation inhibitor.

Table 3 .
List of identified proteins by MALDI-TOF/TOF of the EC4(a)of EC Venom